Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04470050 · ClinicalTrials.gov registry record · Phase 1
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
A Phase 1 study of Opioid Withdrawal, sponsored by BioXcel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 225
- Enrollment target
- 3
- Study locations
NCT04470050 is a Phase 1 study of Opioid Withdrawal that has completed, run by BioXcel Therapeutics. The registered enrollment target is 225 participants, above the 100-participant average among 9 other Opioid Withdrawal trials with a reported enrollment target (125% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT04470050, a Phase 1 study of Opioid Withdrawal, has completed, sponsored by BioXcel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 225 participants
- Enrollment target
- 3
- Study locations
Study Summary
This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance. The opioid (morphine) maintenance phase (Phase 1b) included Days 1-5; the randomized BXCL501/placebo phase (Phase 2) included Days 6-12. The randomized phase was followed by 2 sequential days, Days 13 and 14, utilizing treatment of BXCL501-placebo sublingual films and morphine-placebo capsules for all subjects who remained in the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dexmedetomidine
Study Locations (3)
Florida
- BioXcel Clinical Research Site - Miami Lakes
New Jersey
- BioXcel Clinical Research Site - Marlton
New York
- BioXcel Clinical Research Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2020-06-09 |
| Est. Completion | 2021-02-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04470050
The ClinicalTrials.gov registry entry for NCT04470050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 100-participant average among 9 other Opioid Withdrawal trials with a reported enrollment target (125% higher). The listed sponsor is BioXcel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid Withdrawal appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04470050 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT04470050 about?
NCT04470050 is a clinical study titled "Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal". This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance. The opioid (morphine) maintenance phase (Phase 1b) included Days 1-5; the randomized BXCL501/placebo pha...
What is the current status of trial NCT04470050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 225 participants. The study started on 2020-06-09. Estimated completion is 2021-02-18.
What conditions does trial NCT04470050 study?
This clinical trial studies the following conditions: Opioid Withdrawal.
What interventions are being tested in trial NCT04470050?
The interventions under investigation include: Placebo (DRUG), Dexmedetomidine (DRUG).
Who is sponsoring clinical trial NCT04470050?
This trial is sponsored by BioXcel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04470050 being conducted?
This trial has 3 study locations across Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Withdrawal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain
RECRUITING · Phase 1
-
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
ACTIVE NOT RECRUITING · Phase 1
-
Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain
RECRUITING · NA
-
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
RECRUITING
-
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
RECRUITING · Phase 2
-
Evaluating Buspirone to Treat Opioid Withdrawal
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.